The interleukin-33 antibody of AnaptysBio passes midstage test in asthma The pipeline drug, etokimab of AnaptysBio, has positive data in a third indication that adds asthma to one of its triumphs. The US-based company gets another proof-of-concept study for the interleukin-33 (IL-33) inhibitor, because of phase 2a ...
Find MoreFDA still not completely satisfied with Kamada’s inhaled AAT drug(Synthetic Biologics) Kamada is stuck again with a new obstacle in its way to bring the first inhaled treatment for alpha-1 antitrypsin (AAT) deficiency in the market as an alternative to currently present intravenous drugs. The company specializes in ...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.